Analysts Adjust Targets for CACI International Post Strong Q1 Performance Analysts Adjust Targets for CACI International Post Strong Q1 Performance

Photo of author

By Ronald Tech

CACI International Inc CACI released its first-quarter financial results, surpassing expectations, and provided an optimistic revenue outlook for FY25, announced after Wednesday’s closing bell.

The company achieved quarterly earnings of $5.93 per share, exceeding the analyst consensus of $5.07 per share. Additionally, quarterly sales reached $2.057 billion, surpassing the analyst consensus estimate of $1.921 billion.

John Mengucci, President and CEO of CACI International, expressed satisfaction with the performance, stating, “In the first quarter, CACI delivered exceptional financial results, including revenue growth of 11%, robust profitability and cash flow, and significant awards and backlog. Our recent strategic acquisitions show our flexible approach to capital deployment.” He further added, “Our positive momentum has enabled us to revise our fiscal year 2025 guidance, positioning CACI for continued long-term value creation for customers and shareholders.”

Despite the strong results, CACI International shares experienced a 0.7% decline, trading at $548.67 on Friday.

Several analysts revised their price targets for CACI International following the earnings report:

  • Baird analyst Peter Arment upgraded CACI International to Outperform and adjusted the price target from $533 to $640.
  • Truist Securities analyst Tobey Sommer reaffirmed a Buy rating for CACI International and increased the price target from $520 to $650.
  • Goldman Sachs analyst Gavin Parsons maintained a Neutral rating for CACI International and raised the price target from $471 to $520.
  • TD Cowen analyst Cai von Rumohr maintained a Buy rating for the stock and raised the price target from $545 to $570.

Considering investing in CACI stock? Here are the analysts’ perspectives:



See also  Alnylam Pharmaceuticals: Navigating Through Turbulent WatersAlnylam Pharmaceuticals: Navigating Through Turbulent Waters